Chemello Diego, Rosa Larissa, de Araujo Amanda Faria, de Araujo Pedro Cargnelutti, Pereira Luiz Carlos Carneiro, Hillesheim Suélen Feijó, Saffi Marco Aurélio Lumertz
Universidade Federal de Santa Maria - UFSM, Centro de Ciências da Saúde, Departamento de Clínica Médica, Santa Maria, RS, Brasil.
Universidade Federal de Santa Maria - UFSM, Programa de Pós-graduação em Gerontologia, Santa Maria, RS, Brasil.
J Vasc Bras. 2021 Apr 28;20:e20200036. doi: 10.1590/1677-5449.200036.
Our study describes a fatal case of phlegmasia cerulea dolens and massive venous thrombosis in a patient taking rivaroxaban regularly to treat cerebral venous sinus thrombosis. Blood tests samples were positive for lupus anticoagulant. The unique evolution of the case, as well as the positivity for lupus anticoagulant, raises the possibility of an acquired hypercoagulation syndrome. We highlight the fact that the test recommended as the first line for lupus anticoagulant diagnosis (dilute Russell viper venom time) is the most affected by rivaroxaban, leading to a high prevalence of false-positive results. We also discuss potential diagnoses for the current case and review the current state-of-the-art of use of the novel oral anticoagulation agents in this unusual situation. So far, there are no recommendations to use such agents as first options in cerebral venous sinus thrombosis or in hypercoagulation syndromes.
我们的研究描述了一例服用利伐沙班定期治疗脑静脉窦血栓形成的患者发生的股青肿和大量静脉血栓形成的致命病例。血液检测样本狼疮抗凝物呈阳性。该病例的独特演变以及狼疮抗凝物阳性,增加了获得性高凝综合征的可能性。我们强调,作为狼疮抗凝物诊断一线推荐检测(稀释蝰蛇毒时间)受利伐沙班影响最大,导致假阳性结果的高发生率。我们还讨论了当前病例的潜在诊断,并回顾了在这种不寻常情况下新型口服抗凝剂的当前使用现状。到目前为止,尚无将此类药物作为脑静脉窦血栓形成或高凝综合征首选药物的推荐。